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Abstract
Amonafide is a DNA intercalator in clinical development for the treatment of cancer. The drug has a 5-position
amine that is variably acetylated to form a toxic metabolite in humans, increasing adverse effects and complicating
the dosing of amonafide. Numonafides, 6-amino derivatives of amonafide that avoid the toxic acetylation, also
show in vitro anticancer activity, as we have previously described. Here, we report the in vitro and in vivo activities
of two numonafides, 6-methoxyethylamino-numonafide (MEAN) and 6-amino-numonafide (AN) with comparisons
to amonafide. The in vitro potencies and cellular anticancer mechanisms are similar for the two numonafides and
amonafide. Results from several mouse models of human cancer demonstrate that AN and MEAN require slightly
higher doses than amonafide for equal efficacy in short-term dosing models, but the same dose of all three com-
pounds in long-term dosing models are equally efficacious. MEAN is tolerated much better than amonafide and AN
at equally efficacious doses based on weight change, activity, stool consistency, and dose tolerance with survival
as the end point. The studies presented here demonstrate that MEAN is much less toxic than amonafide or AN in
mouse models of human liver and gastric cancers while being equally efficacious in vivo and inhibiting cancer cells
through similar mechanisms. These findings demonstrate that numonafides can be less toxic than amonafide and
support further preclinical development and novel anticancer agents or as replacements or amonafide.
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Introduction
Naphthalamides are a class of anticancer compounds that have been
the focus of considerable development during the last 25 years [1,2].
One naphthalamide drug, amonafide (AMN), which is a DNA in-
tercalator and a possible inhibitor of topoisomerase II [1,2], has
proceeded to clinical development for the treatment of neoplastic dis-
eases. AMN has shown good activity against advanced breast cancer
[3] and as a second-line therapy for AML [4]; however, the 5-position
amine of AMN is acetylated in humans by N -acetyl-transferase 2
(NAT2), converting the parental molecule to a toxic 5-amino-acetyl
metabolite [1,2]. Polymorphisms in the NAT2 gene cause varying en-
zymatic activity of NAT2 among individuals, which thereby requires
phenotyping of acetylation status or genotyping of NAT2 in each
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patient before AMN treatment [1,2], a process that is costly and delays
treatment initiation.
We have previously described the synthesis of 6-position amino
derivatives of AMN called numonafides (Figure 1A) [5]. The numo-
nafide with a free amine in the 6-position and one with a substituted
amine in the 6-position are not acetylated, whereas the parental com-
pound, AMN, is extensively acetylated as determined by an NAT2
biochemical assay [5]. Our previous characterization of numonafides
showed that 6-amino-numonafide (AN) and 6-methoxyethylamino-
numonafide (MEAN) (Figure 1A) had the best antitumor properties
in vitro [5]. In this report, we have further characterized the in vitro
mechanisms, in vivo antitumor efficacy, and in vivo toxicities of AN
and MEAN in murine tumor models of human cancer using AMN
as a comparative control throughout.
Materials and Methods
Cell Culture and In Vitro Assays
All the cells were cultured in Dulbecco modified Eagle medium
(Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum
(Gibco).
MTT Assay
Briefly, cells were seeded into 96-well plates and treated with AMN,
AN, or MEAN for 72 hours. The medium was removed, and the
cells were incubated with a solution containing 0.5 mg MTT/ml
phosphate-buffered saline at 37°C for 4 hours. The MTT solution
was removed, and the cells were lysed with 100 μl/well dimethyl-
sulfoxide (DMSO) for 15 minutes at 37°C. The optical density was
measured using a Bio-Rad microplate reader at 570 nm with DMSO
as blank. Triplicate wells were assayed for each condition. Data were
analyzed by GraphPad Prism 5 software (GraphPad, La Jolla, CA) to
get the 50% inhibitory concentration (IC50). For DNA content assays,
1 × 106 treated cells were collected, stained using Coulter DNA Prep
Reagents Kit (Beckman Coulter) according to the manufacturer’s
protocol, and then analyzed by FACS (Beckman Coulter FC500
MPL). Apoptosis assays were performed on 2 × 105 treated cells stained
with using annexin V–fluorescein isothiocyanate Kit (BD Biosciences,
San Jose, CA), and then FACS was performed.
Gene Expression Array
RNA was isolated from 106 HepG2 cells with QIAGENs RNeasy
Mini Kit after an overnight treatment with 2 μM of AMN, AN,
MEAN, or vehicle (0.2% DMSO). RNA expression analysis was
performed Illumina Human HT-12 Expression Beadchips, which
Figure 1. Numonafides behave similar to AMN in vitro. (A) Structures of AMN and the two numonafides examined herein. (B) Concen-
trations of AMN, MEAN, and AN that cause 50% growth inhibition in human gastric carcinoma (AGS, MGC, and SGC-7901), leukemia
(K562 and Jurkat), breast carcinoma (MDA-MB-435), hepatoma (HepG2, Huh7, and SMMC-7721), lung carcinoma (A549), and colon
carcinoma (HT-29) cell lines as determined by the MTT assay. (C) Cell cycle analysis of AGS gastric cancer cells after 24 hours of treat-
ment with AMN, AN, or MEAN as determined by flow cytometry for DNA content (bottom dark gray bars = cells in G1 phase, middle
light gray bars = S phase, and white bars = G2/M phases). (D) Results from flow cytometry analysis of apoptosis in Huh7 hepatoma cells
after 24 hours of treatment with AMN or numonafides. All error bars = SD from three or more independent experiments and vehicle =
1% DMSO.
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provides coverage of 48,802 genes and expressed sequence tags. Raw
signal intensities of each probe were obtained using data analysis soft-
ware (Beadstudio; Illumina, San Diego, CA) and imported to the
Lumi package of Bioconductor for data analysis. Before transformation
and normalization [6–8], A/P call detection was performed based on
detection of P value. Of 48,802 probes with less than 0.01, 18,678
were considered as valid signals. For each pair of five comparisons
(AMN and vehicle, AN and vehicle, MEAN and vehicle, MEAN
and AN, and MEAN and AMN), differentially expressed genes were
identified using an analysis of variance (ANOVA) model with empiri-
cal Bayesian variance estimation [9]. Initially, genes were identified as
being differentially expressed on the basis of a statistical significance
(raw, P < .01; false discovery rate–adjusted, P < .05) and 1.5-fold
change (up or down) in expression level in each comparison.
In Vivo Xenograft Models
Huh7-luc cell line. pGL3-control (Promega, Madison, WI) was first
digested with XbaI (Takara, Shiga, Japan) and then blunted with DNA
polymerase Klenow fragment (Takara). The resulting DNA was then
digested with BglII (Takara) and the DNA fragment (1902 bp) encod-
ing luciferase (luc). This fragment was then ligated to the BamHI/SmaI
(Takara) digested backbone of pWPXL (Addgene, Cambridge, MA) to
create pWPXL-luc. Next, 2.5 × 106 of HEK-293T cells were plated in a
10-cm diameter plate. The following day, 20 μg of pWPXL-Luc, 15 μg
of psPAX2 (Addgene), and 6 μg of pMD2.G (Addgene) were diluted
in 1 ml Hank’s buffered saline with 50 μl of 2.5 M CaCl2 and mixed
gently. After 20minutes of incubation at room temperature, the plasmid
solution was added to the HEK-293T (Invitrogen) medium, and after
6 hours, the medium was replaced with medium containing no plas-
mids. Four days later, the medium was collected, and the lentivirus
was purified with 0.45-μm filters. Then, Huh7 cells were infected with
pWPXL-luc lentivirus virus at a multiplicity if infection of 1000:1 in
the presence of polybrene. After 3 days of infection, single cells were
plated into the wells of a 96-well plate and allowed to grow for 3 weeks,
at which point the highest expressing clone was expanded and used for
the studies described here.
AGS-luc cell line. Lentiviral vectors expressing firefly luciferase (luc)
were generated using a four-plasmid system. Briefly, a lentiviral expres-
sion construct encoding luciferase and green fluorescent protein, each
under the control of an individual CAG-enhanced CMV promoter
(pLenti CMV Puro LUC; Addgene), was cotransfected with lentiviral
packaging plasmids (pMD2.G, psPAX2) and a VSV-G envelope ex-
pressing plasmid (CVG) into HEK-293T cells using Lipofectamine
2000 (Invitrogen, Carlsbad, CA). The medium was collected every
24 hours and replaced with fresh media for 3 days. Virus-containing
medium was filtered with 0.45-μm filters, and then the viral particles
were concentrated with sucrose ultracentrifugation. The viral pellet was
resuspended in the medium with polybrene and added to AGS cells for
12 hours. After infection, the virus-containing medium was replaced
with fresh medium for 24 hours. Cells expressing high levels of green
fluorescent protein were isolated by fluorescence-activated cell sort-
ing, and the pooled population was expanded to create the AGS-luc
cell line.
Mice and xenografts. Male nu/nu (nude) mice (18-20 g at experi-
ment initiation) were maintained at the vivarium of First Affiliated
Hospital, College ofMedicine, in a pathogen-free unit, under a 12-hour
light/dark cycle, and were provided with food and water ad libitum.
Mice were inoculated subcutaneously at the right axilla or the perito-
neal cavity with HepG2 (106 cells), AGS-luc (106 cells), or Huh7-luc
cells (106 cells for subcutaneous inoculation and 2 × 106 cells for intra-
peritoneal inoculation). For the experiments using AGS-luc and Huh7-
luc cells, in vivo bioluminescent imaging was performed with a Lumina
imaging system (Nippon Roper, I.C.E., Tokyo, Japan). Fifteen minutes
before imaging, mice were injected with 150-mg/kg luciferin through
an intraperitoneal route. Images were collected and analyzedwith Living
Image software (Slidebook 4.1, Denver, CO). Vehicle control was
20% DMSO.
Results
AMN, AN, and MEAN Share Similar In Vitro Growth
Inhibition and Apoptotic Properties
Our previous studies showed that the numonafides AN and
MEAN (Figure 1A) inhibit the growth of three cancer cell lines with
potencies similar to AMN and demonstrated similar selectivity for
growth inhibition of cancer cells over normal cells [5]. Here, we sys-
tematically investigated the growth inhibition of numonafides and
AMN in 11 cell lines derived from various cancers. The results show
that the numonafides, AN and MEAN, inhibit cancer cell growth
with a similar potency as AMN, although AN tends to be slightly
less potent (Figure 1B). Because AN and MEAN are potent inhibi-
tors of gastric and liver cancer cell lines and because these cancers are
prevalent malignancies with relatively few pharmacologically viable
treatment options, here we evaluate their antitumor properties using
AGS (gastric cancer), Huh7, and HepG2 (hepatomas) cell lines.
We evaluated the in vitro effect of these compounds on cell pro-
liferation and apoptosis. First, AGS cells were treated with varying
doses of AMN, AN, and MEAN and stained to determine the
DNA content. AMN, AN, and MEAN all cause AGS cells to increase
their DNA content in a dose-dependent manner, and all compounds
significantly (P < .05 by one-way ANOVA with Dunnett test) increase
DNA content at 5 μM, indicating that these compounds cause G2
arrest (Figure 1C), which is likely the result of DNA damage through
intercalation or topoisomerase II inhibition by these compounds [10].
Next, Huh7 cells were treated with the numonafides and AMN for
24 hours then stained to determine the apoptosis index. The results
show that AMN, AN, and MEAN all cause significant (P < .05 by
one-way ANOVA with Dunnett test) increases in apoptosis at 5 and
10 μM with AMN and MEAN being significantly (P < .05 by un-
paired t-test with Welch correction) more potent than AN at both
doses (Figure 1D).
AMN, AN, and MEAN Similarly Influence Gene Expression
Pattern in Cancer Cells
Gene array analyses on cancer cells treated with numonafides,
MEAN, and AMN were performed using to identify and compare
the molecular mechanism and cellular pathways that are affected
by the treatment of these compounds. HepG2 cells were treated with
AMN, MEAN, or AN at 2 μM (a pharmacologically achievable con-
centration) overnight, and the changes in the level of approximately
25,000 transcripts were determined with the gene array. MEAN,
AMN, and AN significantly (P < .05 by t-test) changed the level of
347, 199, and 178 transcripts, respectively, by greater than 1.5-fold
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(Figure 2A). The number of transcripts changed is positively correlated
with the in vitro DNA intercalation potencies of these compounds [5],
suggesting that the change in gene expression is due to the differen-
tial efficiency of DNA intercalation by each compound in the cellular
milieu. There is a lack of differences in gene expression when each
treatment group is compared to one another instead of vehicle treat-
ment (Figure 2A), indicating that all three compounds change the ex-
pression of similar genes and are thereby acting through similar
mechanisms. Supporting this theory is the finding that transcripts
changed greater than three-fold are all similarly altered in the three
treatment groups compared to the vehicle group, with a few exceptions
where AN does not modulate the transcript level to the extent of
AMN and MEAN (Figure 2B), likely due to the lower DNA inter-
calation efficiency or cellular potency of AN [5].
Numonafides Are Efficacious in a Hepatoma Xenograft Model,
but MEAN Is Better Tolerated than AMN and AN
The in vivo tolerance and anticancer properties of AMN, AN, or
MEAN were initially tested in a xenograft model, in which nude im-
munocompromised mice were implanted with the human HepG2
hepatoma cells subcutaneously under the front right axilla (armpit).
Mice were treated with vehicle, 50 μmol/kg, or 100 μmol/kg of each
compound or 200 μmol/kg of MEAN (this dose of AMN or AN rap-
idly killed mice). The compounds were administered through the in-
traperitoneal route once per day for 14 days, 2 weeks after the
implantation of the xenografts. After treatment, the mice were sacri-
ficed, and the tumors were resected and weighed. AMN inhibited
tumor growth most potently at the 50- and 100-μmol/kg doses (Ta-
ble 1). MEAN was less efficacious than AMN at 50 and 100 μmol/kg;
however, the 200-μmol/kg dose of MEAN was equally efficacious as
the 100-μmol/kg dose of AMN. This initial end point tumor measure-
ment in this study suggested that MEAN and AN are less potent than
AMN, but based on the lack of mice that died in the MEAN-treated
groups, up to 200-μmol/kg MEAN is tolerated much better than
AMN and AN and can be equally efficacious due to its lower toxicity.
Numonafides Can Inhibit Tumor Growth and Reduce the Size
of Established Tumors
AGSandHuh7 cells expressing luciferase were used to evaluate tumor
inhibition properties of numonafides and AMN in a time-dependent
manner. In this model, mice were imaged every 7 days to quantify tu-
mor growth through luminescent output of the tumor. First, mice were
implanted with the tumors (subcutaneous AGS-luc [Figure 3, B and
C] and Huh7-luc [Figure 3A] or intraperitoneal Huh7-luc [Figure 3D])
and were treated continuously for 28 days with 50 μmol/kg per day
each compound and 100 μmol/kg MEAN through intraperitoneal
administration [11]. The treatment was initiated 2 weeks after im-
plantation of the subcutaneous xenograft and 1 week after the intra-
peritoneal xenograft. In all three tumor xenograft models, 50 μmol/kg
AN is the least effective and 50 μmol/kg MEAN is slightly more effec-
tive than AN, both halting tumor growth. AMN at the 50-μmol/kg
dose and MEAN at the 100-μmol/kg dose were equally effective (P >
.05 by unpaired t-test at day 21), actually causing a significant (P < .05
by unpaired t-test with Welch correction at day 21) decrease in tumor
size from treatment start (Figure 3, A–D).
Table 1. Numonafides Are Efficacious in the HepG2 Human Xenograft Model.
Treatment Dosage (μmol/kg) once a day × 14 d Final Number of Mice (/10) Tumor Weight (g) % Growth Inhibition P, t-Test
Vehicle 0 10 2.185 ± 0.242 — —
AN 100 8 1.455 ± 0.288 33.4 <.01
AN 50 10 1.969 ± 0.274 9.9 <.05
MEAN 200 10 0.427 ± 0.212 80.5 <.01
MEAN 100 10 0.869 ± 0.301 60.2 <.01
MEAN 50 10 1.889 ± 0.181 13.5 <.01
AMN 100 9 0.509 ± 0.199 76.7 <.01
AMN 50 10 1.141 ± 0.216 47.8 <.01
Nude mice were implanted with HepG2 cells in the front axilla and treated through intraperitoneal injection once per day for 14 days, 2 weeks after implantation of tumor. After treatment, tumors were
resected and weighed (each group started with 10 mice). Statistics (unpaired t-test) are for each group compared to vehicle-treated mice.
Figure 2. Amonafide and numonafides alter gene expression with similar patterns. (A) Number of transcripts that are significantly (P <
.05 by t-test, n = 3) changed in HepG2 cells determined by Illumina’s BeadArray after an overnight treatment with 2 μM of each com-
pound compared to vehicle-treated cells and compared to AMN-treated cells as. (B) Change in levels of transcripts that are significantly
upregulated or downregulated by greater than three-fold in cells treated with AMN or numonafides compared to vehicle (average values
from of three independent experiments and P < .05 for fold changes more than three-fold).
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Owing to the high toxicity observed with AMN and AN and the
need to compare equivalent doses over a longer treatment time, a dif-
ferent dosing strategy was used in the same Huh7 and AGS xenograft
models. About 100 μmol/kg of each compound was administered
through the intraperitoneal route on a 7-day-on/7-day-off schedule for
a total of four treatment courses. At 100 μmol/kg, all three drugs inhibit
the growth of the tumor significantly (P < .05 by one-way ANOVA
with Dunnett test) after day 7 compared to vehicle, but the tumor size
in the treatment groups was not significantly different (Figure 3, E and
F ; P > .05 by one-way ANOVA with Dunnett) from one another at
Figure 3. Numonafides are efficacious in xenograft models of liver and gastric cancer with various dosing schedules. Subcutaneous (sc.)
axilla xenografts of (A) Huh7 and (B and C) AGS cells and (D) intraperitoneal xenograft of Huh7 cells expressing luciferase-implanted
nude mice. Two weeks after implantation of subcutaneous xenografts and 1 week after implantation of the intraperitoneal (ip.) xeno-
grafts, mice were treated with 50 μmol/kg each of AMN, AN, and MEAN and 100 μmol/kg of MEAN once per day for 28 consecutive
days. Tumor burden is determined by the total number of photons emitted from the luminescent tumors. Once the number of live mice
in a treatment group dropped below three of six, the analysis is not shown on the plots for the subsequent days. For subcutaneous
xenografts (A and B), tumor size was inhibited significantly (P < .05 by one-way ANOVA with Dunnett test) in mice treated with com-
pound compared to vehicle-treated mice by day 14. AMN inhibited tumor growth significantly more (P < .05) than 50 μmol/kg AN and
MEAN but not more (P > .05) than 100 μmol/kg MEAN (by one-way ANOVA) on day 21. For the intraperitoneal xenograft (D), all treat-
ments significantly inhibited tumor growth compared to vehicle treatment from day 7 to 21 (P < .05 by one-way ANOVA with Dunnett
test). (E and F) Mice were implanted with Huh7 or AGS subcutaneous xenografts and treated with 100 μmol/kg AMN, AN, and MEAN (six
mice per group) with a cycle of once per day for 7 days and no treatment for 7 days (four cycles). All treatments significantly (P < .05 by
one-way ANOVA with Dunnett test) inhibited the growth of the tumor compared to the control after 7 days, but the tumor size among
the treatment groups was not significantly different (P > .05 by one-way ANOVA) at day 21.
Neoplasia Vol. 13, No. 5, 2011 MEAN is Efficacious and Less Toxic than AMN Liu et al. 457
Figure 4. MEAN is much less toxic than AMN or AN. (A) Survival of mice treated with intraperitoneal injection of vehicle or 50, 100, or
200 μmol/kg AMN, AN, or MEAN once a day for 35 continuous days (n = 10 mice per treatment group). (B) Weight of mice implanted
with subcutaneous tumors treated with 50 μmol/kg once per day for 49 consecutive days or with 100 μmol/kg once per day on a cycle of
7 days on and 7 days off (n = 6 mice per treatment group). (C) Activity and stool consistency in mice implanted with Huh7 xenografts
(same mice represented in the left half of B). Once the number of mice alive in a treatment group dropped below three of six, the
analysis is not shown for the subsequent days.
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day 21. All three compounds shrank the tumor volume compared to day
0 using this dosing schedule.
MEAN Is Less Toxic In Vivo Compared to AMN and AN
The toxicity of these compounds was examined by survival anal-
ysis on mice treated with 50, 100, or 200 μmol/kg of AMN, AN,
and MEAN for up to 35 consecutive days. The results show that
AMN and AN were similarly toxic, whereas the MEAN was tolerated
much better (Figure 4A). Only 1 in 10 mice died by the 35th day at
the 100-μmol/kg dose of MEAN compared with the 100-μmol/kg
dose of AMN or AN, which killed all mice by day 20 (Figure 4A). In
addition, the median survival time for mice treated with 200 μmol/kg
MEAN was more than 30 days compared to a median survival of
10 days for mice treated with equivalent doses of AMN and AN
(Figure 4A).
The body weight, activity, and stool consistency were recorded
during the treatments described in Figure 3 to further assess the toxici-
ties of these compounds. When dosed at 50 μmol/kg every day for
up to 49 days, AMN and AN caused approximately 30% decrease
in weight by days 28 and 35, respectively (Figure 4B). In contrast,
MEAN caused approximately a 10% decrease in weight at day 49
compared to vehicle-treated mice (Figure 4B). On the other hand, all
mice in the AMN and AN groups died by day 49 and no mice died
in the MEAN group (not shown). In treatment with 100 μmol/kg on a
7-day-on/7-day-off dosing cycles, the final weight of MEAN-treated
mice was only 10% to 15% lower than vehicle-treated mice after four
treatment courses (Figure 4B). Given the large size of the AGS and
Huh7 tumors (Figure 2D), the differences in final weights between
MEAN- and vehicle-treated mice may be partially attributed to the
smaller tumors in MEAN-treated mice. Furthermore, a rebound to a
healthy weight is observed on removal of MEAN during the 7-day-off
portion of the dosing (Figure 4B), and there is a minimal alteration of
activity and stool consistency (Figure 4C ). In comparison, AN and
AMN treatments demonstrated less body weight recovery during the
7-day-off in weight and caused decreased activity and worse stool con-
sistency. These findings demonstrate that MEAN is much less toxic
than AMN and AN in nude mice, in terms of weight loss, activity lev-
els, gastrointestinal toxicities, and survival, suggesting that MEAN is
a good candidate to be developed as a novel antigastric and hepatic
cancer drug or as a replacement for AMN.
Discussion
Here, we demonstrate that two numonafides, AN and MEAN, in-
hibit tumor cell growth, induce G2 arrest, and apoptosis in vitro with
potencies similar to the parental drug, AMN (Figure 1), indicating
these three compounds inhibit tumor cell growth through similar cel-
lular mechanisms. In addition, the numonafides alter the transcrip-
tome in cancer cells in a similar pattern to AMN (Figure 2), as has
been reported with other derivatives of AMN containing substituted
5-position aryl amines [12], further indicating that this class of drugs
act on cancer cells with similar mechanisms, independent of alter-
ations in aryl amine substitution. Although the association between
most transcripts altered over three-fold (Figure 2B) by these com-
pounds and cancer is unknown; however, two genes have been asso-
ciated with cancer. First, metallothionein 1G, which is upregulated
greater than six-fold in cells treated by all three compounds, has been
described as a tumor suppressor in hepatocellular carcinoma [13] and
other carcinomas [14]. This finding suggests that up-regulation of
metallothionein 1G could be a potential anticancer mechanism of
numonafides and AMN. The second gene, stearoyl-CoA desaturase,
downregulated by all three compounds, plays a critical role in fatty
acid metabolism that increases cancer cell proliferation and malignant
transformation and decreases apoptosis [15]. The down-regulation of
this gene by numonafides and AMN may contribute to the growth
inhibition and apoptosis induction properties of these compounds.
The identification of changes in gene expression patterns by these
compounds not only helps confirm the common cellular targets be-
tween the numonafides and AMN but also provides potentially new
mechanisms for tumor cell inhibition by AMN and numonafides,
such as the changes in expression of known and unknown genes
and noncoding RNA (Figure 2B) and provides potential clinical bio-
markers for response. Future studies will explore the additional mode
of action for these compounds in cells that contribute to their anti-
tumor properties in vitro and in vivo.
In three human cancer cell line xenograft models using short-term
daily doses, we found that AN and MEAN are slightly less potent
in vivo, but MEAN can be equally efficacious as AMN at higher
doses (Figure 3, A–D). A long-term periodic dosing regimen showed
that all three compounds could be equally efficacious at the same
dose, actually shrinking established tumors, in two different xeno-
graft models (Figure 3, E and F ). The xenograft models indicate that
numonafides are efficacious in vivo and that MEAN is more effective
than AN. Numonafides were developed as potentially less toxic de-
rivatives of AMN because they avoid acetylation of the arylamine,
which causes toxicities associated with AMN [2]. Mice were injected
with 50, 100, or 200 μmol/kg AN, MEAN, and AMN once daily for
up to 35 days to initially determine the toxicities of numonafides. AN
is about equally toxic as AMN in nude mice, suggesting that the free
amine of AN is being metabolized in vivo similar to AMN, but
MEAN is much less toxic and better tolerated by mice. MEAN treat-
ment at the dose of 200 μmol/kg kill less mice than the 50-μmol/kg
dose of AN and AMN (Figure 4A). Further evaluation as judged by
weight, activity, and stool consistency in the two different dosing regi-
mens used for the tumor efficacy studies confirmed that AN and
AMN are equally toxic, whereas MEAN is much less toxic than both
of these compounds (Figure 4, B and C). The similar in vivo potencies
and in vitro mechanisms suggest that these compounds inhibit tumor
cell growth by similar mechanisms; however, the large difference in
toxicity in vivo between MEAN and AMN/AN may be due to differ-
ential pharmacokinetics, biodistribution, metabolism, or a combina-
tion thereof. Although this remains to be elucidated, here we have
provided proof of principle that numonafides can be developed as less
toxic counterparts to AMN and have identified MEAN as the first
numonafide for future development as an anticancer drug.
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